NEW YORK and ANN ARBOR, Mich., Oct. 6, 2015 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the appointment of Alex G. Howarth as Chief Financial Officer. With over 25 years of experience in healthcare and financial advisory roles, Mr. Howarth brings to Lycera a distinguished track record… Read More

Transformational collaboration will focus on the advancement of Lycera’s innovative pipeline, including Lycera’s first-in-class RORgamma agonists for cancer immunotherapy, and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD) NEW YORK and ANN ARBOR, Mich., June 9, 2015 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines announced today the… Read More

NEW YORK and ANN ARBOR, Mich., April 30, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough immunomodulatory medicines to treat autoimmune diseases and cancer, today announced the initiation of a Phase 1 clinical trial of LYC-30937 in healthy volunteers.  LYC-30937 is an oral gut-directed ATPase modulator that is being studied for the treatment… Read More

NEW YORK and ANN ARBOR, Mich., April 7, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that the Company will present preclinical research from its novel cancer immunotherapy program at the American Association of Immunologists (AAI) Annual Meeting, which will take place in New… Read More

NEW YORK and ANN ARBOR, Mich., Mar. 25, 2015 — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company’s collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment. The program, announced in… Read More

NEW YORK and ANN ARBOR, Mich., March 18, 2015 /PRNewswire/ — Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that the Company will present preclinical research from its novel cancer immunotherapy program at the American Association for Cancer Research (AACR) Annual Meeting, which will take place in… Read More

Dr. Wilkins to lead advancement of Lycera’s clinical programs, including first clinical trial anticipated to begin in 2Q 2015 NEW YORK and ANN ARBOR, Mich., Mar. 9, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that H. Jeffrey Wilkins, M.D., has been appointed to the… Read More

Selective RORγ agonist product candidates demonstrated activity as single agent therapy NEW YORK, NY; ANN ARBOR, Mich. – February 9, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that promising data for the anti-tumor activity of the company’s oral, selective RORγ (“ROR gamma”) agonist product… Read More

NEW YORK, NY; ANN ARBOR, Mich. – February 3, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that Paul Sekhri has been named President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Sekhri brings more than 25 years… Read More

ANN ARBOR, Mich. – February 2, 2015 – Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced that Bruce A. Goldsmith, Ph.D., Chief Business Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 11:15 a.m. Eastern Time. The conference… Read More